Zafgen Inc (ZFGN) : Vhcp Management scooped up 60,634 additional shares in Zafgen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 602,114 shares of Zafgen Inc which is valued at $4 Million.Zafgen Inc makes up approximately 3.65% of Vhcp Management’s portfolio.
Other Hedge Funds, Including , Citadel Advisors boosted its stake in ZFGN in the latest quarter, The investment management firm added 31,885 additional shares and now holds a total of 54,527 shares of Zafgen Inc which is valued at $358,788. Spark Investment Management sold out all of its stake in ZFGN during the most recent quarter. The investment firm sold 91,500 shares of ZFGN which is valued $602,070.Ft Options reduced its stake in ZFGN by selling 10,340 shares or 12.96% in the most recent quarter. The Hedge Fund company now holds 69,440 shares of ZFGN which is valued at $456,915. Zafgen Inc makes up approx 0.77% of Ft Options’s portfolio.Foresite Capital Management Iii reduced its stake in ZFGN by selling 48,863 shares or 4.44% in the most recent quarter. The Hedge Fund company now holds 1,050,837 shares of ZFGN which is valued at $6.4 Million. Zafgen Inc makes up approx 4.92% of Foresite Capital Management Iii’s portfolio. Pacad Investment Ltd. sold out all of its stake in ZFGN during the most recent quarter. The investment firm sold 32,733 shares of ZFGN which is valued $200,653.
Zafgen Inc closed down -0.07 points or -0.99% at $7.03 with 3,25,599 shares getting traded on Wednesday. Post opening the session at $7.14, the shares hit an intraday low of $6.91 and an intraday high of $7.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Zafgen Inc reported $-0.65 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on May 10, 2016. Analyst had a consensus of $-0.72.During the same quarter in the previous year, the company posted $-0.53 EPS.
Many Wall Street Analysts have commented on Zafgen Inc. Shares were Reiterated by RBC Capital Mkts on Mar 10, 2016 to “Outperform” and Lowered the Price Target to $ 19 from a previous price target of $21 .
Zafgen Inc. is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate Beloranib is a twice-weekly subcutaneous (SC) injection being developed for the treatment of multiple indications including severe obesity in two rare diseases Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO) including craniopharyngioma-associated obesity and severe obesity. Beloranib is in Phase III stage of development for obesity and hyperphagia in patients with PWS; completed Phase II clinical trial for HIAO and is in Phase IIb stage of development for severe obesity in the general population. The Company’s other product candidate ZGN-839 is in pre-clinical development stage. The Company is also evaluating the additional MetAP2 inhibitors beyond Beloranib as potential development candidates for the treatment of severe obesity.